Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNU6-596P is a pseudogene corresponding to the U6 small nuclear RNA (snRNA) gene family. U6 snRNA is an essential non-coding RNA component of the spliceosome, a complex responsible for intron removal from pre-mRNA in eukaryotes[1][3]. However, RNU6-596P itself is a non-functional derivative and does not produce an active snRNA product. Like many pseudogenes derived from U6 in vertebrate genomes, RNU6-596P retains sequence similarity (including authentic 5'- and 3'-ends of U6 RNA and direct repeats from U6) but has accumulated mutations and structural changes that prevent it from functioning in the spliceosome or any other known biological process[2][4][5]. These U6-derived pseudogenes are common and are considered genomic relics with no established physiological or pathological role. There are no known drugs, biomarkers, or disease associations relevant to this pseudogene, nor are there safety concerns arising from its presence. No evidence suggests it should be considered a therapeutic target or functional biomolecule.
none
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 596, pseudogene (RNU6-596P).